Switching from Spironolactone to Eplerenone
Rationale for Switching to Eplerenone
- Eplerenone was specifically designed with a 9,11-epoxide group to avoid the hormone-associated side effects of spironolactone, making it a more selective mineralocorticoid receptor antagonist 2
- Continuing prednisone while using a mineralocorticoid receptor antagonist is supported by evidence showing that spironolactone effectively treated steroid-induced central serous chorioretinopathy (CSC) in 82% of patients who remained on glucocorticoids 2
Dosing Conversion Protocol
- Start eplerenone at 25 mg once daily as the equivalent dose to spironolactone 25 mg 3
- The target dose for eplerenone is 50 mg once daily, similar to spironolactone 3
Monitoring Requirements
- Continue monitoring at 1, 2, 3, and 6 months after achieving maintenance dose, and every 6 months thereafter 3
- If potassium rises to >5.5 mmol/L, reduce dose to 25 mg on alternate days 3
- If potassium rises to >6.0 mmol/L, stop eplerenone immediately 3
Clinical Efficacy Comparison
- Both medications have demonstrated similar efficacy in treating conditions requiring mineralocorticoid receptor antagonism 1
- In heart failure, eplerenone led to a 15% relative risk reduction in death (EPHESUS trial), while spironolactone showed a 30% relative risk reduction (RALES trial) 3
- For central serous chorioretinopathy, both medications have shown efficacy, with complete resolution of subretinal fluid in 29-82% of cases 4
Special Considerations with Prednisone
- Continuing prednisone while using mineralocorticoid receptor antagonists requires careful monitoring of potassium levels due to potential electrolyte imbalances 2
- In steroid-induced central serous chorioretinopathy, mineralocorticoid receptor antagonists have shown efficacy even with continued glucocorticoid use 2